MediciNova Inc - ESG Rating & Company Profile powered by AI
This webpage is a zero-cost ESG assessment for MediciNova Inc. Alternative companies in the rating industry group for MediciNova Inc are displayedin the table. The analysis of MediciNova Inc is prepared by All Street Sevva using leading AI.
MediciNova Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 2.7, social score of 4.8 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | MediciNova Inc | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does MediciNova Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes MediciNova Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes MediciNova Inc report the average age of the workforce?
Sign up for free to unlockDoes MediciNova Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes MediciNova Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes MediciNova Inc disclose cybersecurity risks?
Sign up for free to unlockDoes MediciNova Inc offer flexible work?
Sign up for free to unlockDoes MediciNova Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes MediciNova Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes MediciNova Inc conduct supply chain audits?
Sign up for free to unlockDoes MediciNova Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes MediciNova Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes MediciNova Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes MediciNova Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes MediciNova Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes MediciNova Inc disclose water use targets?
Sign up for free to unlockDoes MediciNova Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid MediciNova Inc have a product recall in the last two years?
Sign up for free to unlockDoes MediciNova Inc disclose incidents of discrimination?
Sign up for free to unlockDoes MediciNova Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas MediciNova Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes MediciNova Inc disclose parental leave metrics?
Sign up for free to unlockDoes MediciNova Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes MediciNova Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes MediciNova Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes MediciNova Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes MediciNova Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes MediciNova Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs MediciNova Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes MediciNova Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes MediciNova Inc disclose its waste policy?
Sign up for free to unlockDoes MediciNova Inc report according to TCFD requirements?
Sign up for free to unlockDoes MediciNova Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes MediciNova Inc disclose energy use targets?
Sign up for free to unlockDoes MediciNova Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes MediciNova Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for MediciNova Inc
These potential risks are based on the size, segment and geographies of the company.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.